Efficacy and Tolerability of a New Non-Extrafine Formulation of Beclomethasone HFA-134a in Patients with Asthma . Jean Paul Rocca-Serra, Eric Vicaut, Gerard Lefrancois, Alberto Umile.

QVAR ® RediHaler ™ administers the same active ingredient found in the previously available QVAR ® (beclomethasone dipropionate HFA) Inhalation Aerosol, but utilizes innovative breath-actuated ...

Teva announced the launch of Qvar RediHaler (beclomethasone dipropionate HFA) Inhalation Aerosol for the maintenance treatment of asthma as a prophylactic therapy in patients aged 4 years and older.

Qvar with a dose counter (beclomethasone dipropionate HFA; Teva) is now commercially available in the United States.Qvar with a dose counter was approved in May 2014 by the Food and Drug ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol ...

QVAR® is an inhaled corticosteroid (ICS) recommended as a twice-daily treatment for long-term asthma control. Adherence to daily control medications, like QVAR®, is important because when asthma ...

The ICS beclomethasone dipropionate HFA does not require a spacer and is characterized by small particle sizes that result in more of the drug being deposited in both the large and small airways.

Qvar Redihaler (beclomethasone HFA, Teva) has been approved in children aged 4 years and older. This device, however, requires some skill and cannot be used with a holding chamber device.

JERUSALEM — Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of ...

The best delivery of a drug in ventilated neonates is obtained when using a small particle diameter solution administered via a spacer. Lung deposition of hydrofluoroalkane beclomethasone ...

A total of 498 patients entered the run-in phase, of whom 473 received randomised treatment and 443 were included in the ITT analysis [293 (66.1%) to beclomethasone HFA and 150 (33.9%) to ...

TEVA HIGHLIGHTS QNAZETM HFA PHASE III DATA AT THE 2010 ANNUAL MEETING OF THE AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY -- Results Demonstrate Teva's Investigational Nasal Aerosol is ...